TABLE 5.
Long-term protection from HBV infection after hepatitis B vaccination in persons who responded to a primary vaccination series
| Group and location (reference) | No. of patients | Length of follow-up (yr) | % of patients showing anti-HBs loss | No. of carriers | HBsAg | anti-HBc |
|---|---|---|---|---|---|---|
| Infants of HBeAg-positive mothers | ||||||
| U.S.A. (143)a | 315 | 4–11 | 12 | 0 | 0 | 30 |
| China (92) | 74 | 9 | 49 | 0 | 0 | 7 |
| China (162) | 536 | 9 | 44 | 14 | 14 | NA |
| China (165) | 50 | 5 | 17 | 1 | 3 | |
| Taiwan (94) | 199 | 6 | 3 | 0 | 0 | 0 |
| Taiwan (70) | 654 | 5 | 9 | 3 | 3 | 46 |
| Taiwan (65) | 165 | 5 | 17 | 0 | 0 | 11 |
| Routine infant or early childhood vaccine | ||||||
| Senegal (26) | 327 | 2–12 | NA | 9 | 7 | |
| China (162) | 536 | 8 | 39 | 3 | 3 | NA |
| Venezuela (55)b | 280 | 6 | 29 | 0 | 0 | 6 |
a
Contains unpublished follow-up data.
b
NA, data not available.